1.Fangzheng W, Chuner J, Haiyan Q, Quanquan S, Zhimin Y, Tongxin L, et al. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area. Medicine. 2019;98(51):e18484.
2.Beddok A, Feuvret L, Noel G, Bolle S, Deberne M, Mammar H, et al. Efficacy and toxicity of proton with photon radiation for locally advanced nasopharyngeal carcinoma. Acta Oncol. 2019;58(4):472–4.
3.Yang Q, Zhao TT, Qiang MY, Hu L, Lv X, Ye YF, et al. Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. J Cancer. 2018;9(17):3023–31.
4.Liu SL, Sun XS, Xie HJ, Chen QY, Lin HX, Liang H, et al. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level. BMC cancer. 2020;20(1):89.
5.Fuzissaki MA, Paiva CE, Oliveira MA, Lajolo Canto PP, Paiva Maia YC. The Impact of Radiodermatitis on Breast Cancer Patients’ Quality of Life During Radiotherapy: A Prospective Cohort Study. J Pain Symptom Manage. 2019;58(1):92–9.e1.
6.Ho AY, Olm-Shipman M, Zhang Z, Siu CT, Wilgucki M, Phung A, et al. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. International journal of radiation oncology, biology, physics. 2018;101(2):325–33.
7.Chen H, Wu M, Li G, Hua L, Chen S, Huang H. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. Medicine (Baltimore). 2017;96(44):e8202.
8.Kuang WL, Zhou Q, Shen LF. Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma. Clin Transl Oncol. 2012;14(10):783–90.
9.Zhang L, Shan GP, Li P, Cheng PJ. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma. Med Oncol. 2015;32(3):41.
10.Borm KJ, Loos M, Oechsner M, Mayinger MC, Paepke D, Kiechle MB, et al. Acute radiodermatitis in modern adjuvant 3D conformal radiotherapy for breast cancer - the impact of dose distribution and patient related factors. Radiat Oncol. 2018;13(1):218.
11.Moon SH, Cho KH, Lee CG, Keum KC, Kim YS, Wu HG, et al. IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma: Survival outcome in a Korean multi-institutional retrospective study (KROG 11–06). Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2016;192(6):377–85.
12.Chen JL, Huang YS, Kuo SH, Hong RL, Ko JY, Lou PJ, et al. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma. Oncotarget. 2017;8(8):14068–77.
13.Frikha M, Auperin A, Tao Y, Elloumi F, Toumi N, Blanchard P, et al. A randomized trial of induction docetaxel-cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006–02). Ann Oncol. 2018;29(3):731–6.
14.Kong L, Zhang YW, Hu CS, Guo Y. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chinese journal of cancer. 2010;29(5):551–5.
15.Zhang J, Chen S, Li G, Zhang W, Qin T, Yin P, et al. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Cancer Chemother Pharmacol. 2017;79(6):1087–97.
16.Li H, Li L, Huang X, Li Y, Zou T, Zhuo X, et al. Radiotherapy-induced dysphagia and its impact on quality of life in patients with nasopharyngeal carcinoma. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2019;195(6):457–67.
17.McDowell LJ, Rock K, Xu W, Chan B, Waldron J, Lu L, et al. Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. International journal of radiation oncology, biology, physics. 2018;102(2):340–52.
18.Sauter M, Lombriser N, Butikofer S, Keilholz G, Kranzbuhler H, Heinrich H, et al. Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2020.
19.Ta MH, Schernberg A, Giraud P, Monnier L, Darai E, Bendifallah S, et al. Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis. Acta oncologica (Stockholm, Sweden). 2019;58(8):1127–34.
20.Ito M, Kodaira T, Tachibana H, Tomita N, Makita C, Koide Y, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head & neck. 2017;39(12):2406–15.
21.Ren F, Li S, Zhang Y, Zhao Z, Wang H, Cui Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiation oncology (London, England). 2019;14(1):84.
22.Blakaj A, Bonomi M, Gamez ME, Blakaj DM. Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data. Oral oncology. 2019;95:29–34.
23.Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43.
24.Levy A, De Felice F, Bellefqih S, Guigay J, Deutsch E, Nguyen F, et al. Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer. Head & neck. 2016;38 Suppl 1:E905–10.
25.Chang H, Peng L, Tao YL, Chen C, Xiao WW, Hu YH, et al. Necessity of concurrent chemotherapy in N2–3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of >/ = 3 cycles followed by intensity-modulated radiotherapy. Cancer Med. 2019;8(6):2823–31.
26.Bonomo P, Talamonti C, Desideri I, Marrazzo L, Pezzulla D, Rampini A, et al. Analysis of skin dose distribution for the prediction of severe radiation dermatitis in head and neck squamous cell carcinoma patients treated with concurrent chemo-radiotherapy. Head & neck. 2020;42(2):244–53.
27.Wang F, Jiang C, Ye Z, Liu T, Sun Q, Yan F, et al. Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience. Transl Oncol. 2018;11(1):65–73.
28.Jo IY, Kim SW, Son SH. Dosimetric evaluation of the skin-sparing effects of 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for left breast cancer. Oncotarget. 2017;8(2):3059–63.
29.Hardee ME, Raza S, Becker SJ, Jozsef G, Lymberis SC, Hochman T, et al. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. Int J Radiat Oncol Biol Phys. 2012;82(3):e415–23.
30.Kumar T, Schernberg A, Busato F, Laurans M, Fumagalli I, Dumas I, et al. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. Cancer management and research. 2019;11:6285–97.
31.Ishizu Y, Ishigami M, Hayashi K, Honda T, Kuzuya T, Ito T, et al. Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection. Hepatology research: the official journal of the Japan Society of Hepatology. 2020;50(1):47–56.
32.Ghosh-Laskar S, Yathiraj PH, Dutta D, Rangarajan V, Purandare N, Gupta T, et al. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. Head Neck. 2016;38 Suppl 1:E1481–7.
33.Liang SB, Wang Y, Hu XF, He SS, Yang XL, Liu LZ, et al. Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China. J Cancer. 2017;8(18):3718–24.
34.Katano A, Takahashi W, Yamashita H, Yamamoto K, Ando M, Yoshida M, et al. Radiotherapy alone and with concurrent chemotherapy for nasopharyngeal carcinoma: A retrospective study. Medicine. 2018;97(18):e0502.
35.Clavel S, Nguyen DH, Fortin B, Despres P, Khaouam N, Donath D, et al. Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. International journal of radiation oncology, biology, physics. 2012;82(2):582–9.
36.Yan H, Cao X, Wang J. Application of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Oncology letters. 2017;14(6):7773–6.
37.Chen NB, Qiu B, Zhang J, Qiang MY, Zhu YJ, Wang B, et al. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities. Cancer research and treatment: official journal of Korean Cancer Association. 2020;52(1):31–40.
38.Korpics MC, Turchan WT, Rooney MK, Koshy M, Spiotto MT. Patterns of Care and Outcomes of Intensity-Modulated Radiotherapy and 3D Conformal Radiotherapy for Early Stage Glottic Cancer: A National Cancer Database Analysis. Cancers (Basel). 2019;11(12).
39.You R, Cao YS, Huang PY, Chen L, Yang Q, Liu YP, et al. The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis. Theranostics. 2017;7(19):4825–35.